BiotechTube
Treovir

Treovir

San Diego, United States· Est.
treovir.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Treovir is a private, pre-revenue biotech advancing G207, a targeted oncolytic immunotherapy for recurrent pediatric brain tumors. The therapy demonstrated improved survival with no serious side effects in a Phase 1 study and has now entered a pivotal Phase 2 trial in 2024, supported by FDA Fast Track and orphan drug designations. With a seasoned leadership team deeply experienced in oncolytic virology and brain tumor research, Treovir is positioned to address a critical unmet need in pediatric oncology where there are currently zero FDA-approved therapies.

OncologyPediatric Brain TumorsNeuro-Oncology

Technology Platform

Genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) immunotherapy designed for selective replication in tumor cells and induction of systemic anti-tumor immunity.

Funding History

1
Total raised:$30M
Series A$30M

Opportunities

G207 has the potential to become the first FDA-approved therapy for pediatric brain tumors, addressing a catastrophic unmet need with zero current treatment options.
Regulatory designations (Fast Track, Orphan Drug) in the US and Europe can accelerate development and provide extended market exclusivity, enhancing commercial potential.

Risk Factors

The company's value is concentrated in a single asset (G207) currently in a pivotal Phase 2 trial; clinical failure would be existential.
As a small, private, pre-revenue company, Treovir faces significant financing needs and potential challenges in independently commercializing a therapy for a specialized pediatric oncology market.

Competitive Landscape

The competitive landscape for pediatric brain tumors is currently empty of approved targeted therapies, giving G207 a first-mover opportunity. However, Treovir competes broadly with developers of other immunotherapies (e.g., CAR-T, other oncolytic viruses) and targeted agents in adult glioblastoma that may eventually be tested in pediatric populations.

More companies in Biologics / Biosimilars →More companies in United States →